BioCentury
ARTICLE | Emerging Company Profile

Ins and Outs of cardiovascular gene therapy; CardioGene: The Inside; Eurogene: The outside

September 29, 1997 7:00 AM UTC

Gene therapy has two critical requirements: delivery of the gene vector to the appropriate tissues or location within the body, and expression of a gene product that has therapeutic benefit. Cardiovascular disease is thought to be an excellent opportunity since targeted delivery to blood vessels is easier than for other organs, and a number of genes relevant to cardiovascular indications have been identified.

CardioGene Therapeutics has both pieces of the puzzle: gene expression vectors with promising genes to deliver, and devices designed by the founding scientists/cardiologists to deliver those vectors specifically to blood vessels. The company is focused in restenosis, plaque stabilization, and angiogenesis to treat ischemia, aneurysm and heart failure...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article